The Innovation and Value Initiative (IVI) has updated its existing prototype economic model examining value among rheumatoid arthritis (RA) therapies to include biosimilars.
The Innovation and Value Initiative (IVI) has updated its existing prototype economic model examining value among rheumatoid arthritis (RA) therapies to include biosimilars, triple therapy, Janus kinase (JAK) inhibitors, sarilumab, as well as updated treatment effect estimates based on additional randomized controlled trial (RCT) evidence, and updated cost estimates.
The update follows a research brief released last month that questioned whether "conventional head-to-head cost-effectiveness analyses may not align with decision making in chronic disease," citing an analysis of JAK inhibitors for the treatment of rheumatoid arthritis (RA).
The issue of who gets to decide "value" in an era of ever-increasing drug costs has become a point of debate in recent years.
The IVI model, IVI-RA, is intended to help payers and other stakeholders identify high-value therapies by simulating the lifetime costs and benefits of different strategies for treating patients with moderate-to-severe RA. IVI said its latest research highlights the type of additional questions important for patients, providers, and payers that make value assessments; it also incorporates real-world data.
The model is designed to examine a variety of factors with the inclusion of real-world patient data, including:
IVI will continue to update the model in 2020 to include the duration of maintenance treatment and the impact of prior treatment.
“Value assessments must be relevant to real-world decision makers and can be vastly improved by an ability to showcase how real patients experience disease,” says Jennifer Bright, IVI’s executive director, in a statement. “We recognize that our open-source model is just a start, which is why we are calling for partners to work with us, sharing real-world data on outcomes so we can answer even more questions. Our aim is to perfect this model to answer questions truly important to patients, providers, and payers.”
IVI-RA was the first disease-specific economic model developed within IVI’s Open-Source Value Project (OSVP), which serves as a laboratory for developing next-generation economic models in an open-source environment. The model was initially released in November 2017.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Adalimumab Biosimilar Switching Policy Shows Long-Term Success in IBD
February 26th 2025Patients with inflammatory bowel disease (IBD) who switched from reference adalimumab (Humira) to a biosimilar under a mandatory nonmedical switching policy maintained long-term safety, efficacy, and treatment persistence comparable to those who remained on the originator drug, according to a Canadian study.